by Michael Boyd | Jul 25, 2023 | Publications
Resolving whether MTBE exhibits endocrine activity is important given regulatory and public interest in endocrine disrupting substances and their potential for causing adverse effects in humans or wildlife. A weight-of-evidence (WoE) analysis was conducted, focusing...
by Michael Boyd | Jul 25, 2023 | Publications
A group promoting the importance of non-monotonic dose responses for endocrine disruptors contend that scoring systems giving primacy to GLP are biased against non-GLP studies from the literature and are merely record-keeping exercises to prevent fraudulent reporting...
by Michael Boyd | Jul 25, 2023 | Publications
There is a recognized need to improve the application of epidemiologic data in human health risk assessment especially for understanding and characterizing risks from environmental and occupational exposures. Although there is uncertainty associated with the results...
by Michael Boyd | Jul 25, 2023 | Publications
To place endocrine screening results in the context of potency and human exposure, we propose a method that entails (1) calculating a benchmark dose for a response measured in an endocrine screen; (2) estimating the human urinary concentration (biomonitoring...
by Michael Boyd | Jul 25, 2023 | Publications
In 2009, companies began screening compounds using the US Environmental Protection Agency’s Endocrine Disruptor Screening Program (EDSP). EDSP has two tiers: Tier 1 includes 11 assays to identify compounds with potential endocrine activity. This article...
Recent Comments